AR055407A2 - Composicion farmaceutica acuosa tipo gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento - Google Patents

Composicion farmaceutica acuosa tipo gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento

Info

Publication number
AR055407A2
AR055407A2 ARP060103816A ARP060103816A AR055407A2 AR 055407 A2 AR055407 A2 AR 055407A2 AR P060103816 A ARP060103816 A AR P060103816A AR P060103816 A ARP060103816 A AR P060103816A AR 055407 A2 AR055407 A2 AR 055407A2
Authority
AR
Argentina
Prior art keywords
composition
preparation
active substance
subcutaneous administration
pharmaceutical composition
Prior art date
Application number
ARP060103816A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR055407A2 publication Critical patent/AR055407A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion farmacéutica acuosa tipo gel para la administracion subcutánea, que comprende ácidos bisfosfonicos o sus sales farmacéuticamente aceptables. La composicion tiene por lo menos un compuesto que inhibe la difusion de la sustancia activa en el tejido, estando presente la sustancia activa en forma disuelta en la composicion, y teniendo la composicion una viscosidad >-220 mPa*s. También se dan a conocer un procedimiento para la produccion de esta composicion y el uso de dichas composiciones para la preparacion de un medicamento. Mediante esta composicion es posible administar localmente concentraciones relativamente elevadas de bisfosfonatos sin que se produzcan incompatibilidades, para tratar desordenes del metabolismo oseo. Reivindicacion 1: Composicion farmacéutica acuosa tipo gel para la administracion subcutánea, que comprende ácidos bisfosfonicos seleccionados a partir de: clodronato, etidronato, risedronato, zoledronato, tiludronato, pamidronato, cimadronato (YM175) y alendronato, o sus sales fisiologicamente aceptables, caracterizada porque contiene por lo menos un compuesto que inhibe la difusion de la sustancia activa en los tejidos, el cual es un polímero natural y está seleccionado a partir del grupo formado por derivados de celulosa, derivados de ácido algínico, dextranos, gelatinas, colágeno, ácidos hialuronicos y/o sulfatos de dermatan y heparan, estando la sustancia activa presente en forma disuelta en la composicion y teniendo la composicion una viscosidad >- 220 mPa*s.
ARP060103816A 2000-05-05 2006-08-31 Composicion farmaceutica acuosa tipo gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento AR055407A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10021917 2000-05-05

Publications (1)

Publication Number Publication Date
AR055407A2 true AR055407A2 (es) 2007-08-22

Family

ID=7640900

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010102090A AR033671A1 (es) 2000-05-05 2001-05-03 Composicion farmaceutica acuosa del tipo de gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento
ARP060103816A AR055407A2 (es) 2000-05-05 2006-08-31 Composicion farmaceutica acuosa tipo gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010102090A AR033671A1 (es) 2000-05-05 2001-05-03 Composicion farmaceutica acuosa del tipo de gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento

Country Status (16)

Country Link
US (1) US6676970B2 (es)
EP (1) EP1284754B1 (es)
JP (1) JP3923800B2 (es)
KR (1) KR100492110B1 (es)
CN (1) CN1180846C (es)
AR (2) AR033671A1 (es)
AT (1) ATE314862T1 (es)
AU (1) AU778431B2 (es)
BR (1) BR0110618A (es)
CA (1) CA2407747C (es)
DE (1) DE60116483T2 (es)
DK (1) DK1284754T3 (es)
ES (1) ES2254410T3 (es)
MX (1) MXPA02010740A (es)
WO (1) WO2001085217A1 (es)
ZA (1) ZA200208499B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365770A2 (en) * 2001-02-07 2003-12-03 Durect Corporation Devices and methods for management of bone density
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
KR20070043043A (ko) * 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
US7294195B2 (en) * 2005-08-08 2007-11-13 Wacker Chemical Corporation Water repellant gypsum compositions
ITMI20052515A1 (it) * 2005-12-29 2007-06-30 Abiogen Pharma Spa Formulazione farmaceutica per il trattamento della osteoartrite
EP1923049A1 (en) * 2006-11-17 2008-05-21 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
CA2669488A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
EP1992364A1 (en) * 2007-05-16 2008-11-19 Biosuma S.r.l. Carboxylated polysaccharides phosphated or bisphosphonated derivatives, optionally cross-linked, and their preparation and biomedical uses
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20100247607A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102000094B (zh) * 2010-09-27 2013-03-27 天津南开允公医药科技有限公司 一种含有伊班膦酸的药物组合物及制备工艺
US20120089118A1 (en) * 2010-10-08 2012-04-12 A Nevada Corporation Delivery of bisphosphonates by microinjection systems
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
GB201412236D0 (en) * 2014-07-09 2014-08-20 Univ Nottingham Method of producing and using alginate hydrogels
CN106687127A (zh) * 2014-09-03 2017-05-17 日东电工株式会社 含有双膦酸盐剂的体液免疫用疫苗药物组合物
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
IT201800009444A1 (it) 2018-10-15 2020-04-15 Fidia Farm Spa Coniugati tra acido ialuronico e amminobisfosfonati e loro impiego terapeutico

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE61111C (de) B. WINKLER in Berka a. Werrä Verfahren zur Herstellung von Knöpfen ohne Fadenbefestigung
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
DE4223940A1 (de) * 1992-07-21 1994-01-27 Boehringer Mannheim Gmbh Neue acyclische Amidingruppen-haltige Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4228552A1 (de) * 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
DE4244422A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel
DE4244423A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation

Also Published As

Publication number Publication date
AU778431B2 (en) 2004-12-02
BR0110618A (pt) 2003-04-29
ZA200208499B (en) 2004-02-26
CN1180846C (zh) 2004-12-22
KR20030009470A (ko) 2003-01-29
EP1284754A1 (en) 2003-02-26
US20010053388A1 (en) 2001-12-20
ATE314862T1 (de) 2006-02-15
MXPA02010740A (es) 2003-03-10
WO2001085217A1 (en) 2001-11-15
CA2407747C (en) 2008-03-11
CA2407747A1 (en) 2001-11-15
JP3923800B2 (ja) 2007-06-06
KR100492110B1 (ko) 2005-06-02
DE60116483D1 (de) 2006-03-30
ES2254410T3 (es) 2006-06-16
DK1284754T3 (da) 2006-05-01
US6676970B2 (en) 2004-01-13
AR033671A1 (es) 2004-01-07
JP2003532689A (ja) 2003-11-05
CN1427727A (zh) 2003-07-02
EP1284754B1 (en) 2006-01-04
AU5631701A (en) 2001-11-20
DE60116483T2 (de) 2006-09-07

Similar Documents

Publication Publication Date Title
AR055407A2 (es) Composicion farmaceutica acuosa tipo gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento
RU2238736C2 (ru) Фармацевтическая парентеральная композиция, содержащая бифосфонат
Adami et al. Adverse effects of bisphosphonates: a comparative review
PT1339411E (pt) ''utilização de ácido zoledrónico para tratamento da dor''
PT623347E (pt) Utilizacao de derivados do acido bisfosfonico para a preparacao de medicamentos destinados a favorecer a reparacao ossea
EA008354B1 (ru) Инъецируемые твердые переносчики гиалуроновой кислоты для доставки остеогенных протеинов
ES2379485T3 (es) Implante dental y procedimiento para su fabricación
Zheng et al. A dual crosslinked hydrogel-mediated integrated peptides and BMSC therapy for myocardial regeneration
ES2269014T1 (es) Procedimiento para inhibir la resorcion osea.
US20130040915A1 (en) Pharmaceutical composition
US20100179110A1 (en) Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
RU2008126108A (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту
Timchenko Bisphosphonates as potential inhibitors of calcification in bioprosthetic heart valves
AR062697A1 (es) Compuestos como aptameros-dimeros y sus usos en el diagniosticos y la terapia
RU2697873C2 (ru) Композиции и продукты для применения в лечении переломов и дефектов кости
WO2010026701A1 (ja) ［４－（メチルチオ）フェニルチオ］メタンビスホスホン酸又は薬学的に許容され得るその塩を有効成分とする骨形成促進剤
Papathanasiou et al. Polymeric matrices for the controlled release of phosphonate active agents for medicinal applications
BR0215707A (pt) Composição farmacêutica para a liberação controlada de ingredientes ativos e processo para a preparação de uma composição farmacêutica
Utari et al. The potential of bisphosphonate risedronate edible film strips to inhibit post-orthodontic tooth relapse (literature review)
WO2004019957A1 (ja) ビスホスホン酸誘導体又はその塩を有効成分とする歯周ポケット投与用医薬組成物
EA044402B1 (ru) Конъюгаты гиалуроновой кислоты и амино-бисфосфонатов и их терапевтическое применение
CN110520132A (zh) 包括双膦酸盐的用于预防或治疗慢性同种异体移植物能够障碍的组合物
TH51552A (th) การใช้กรดบิสฟอสโฟนิคสำหรับการบำบัดแอนจิโอจีนีซิส
KR20130110326A (ko) 칼시토닌의 경구투여용 조성물

Legal Events

Date Code Title Description
FC Refusal